Aptus Pharma Q2 FY27 Share Price & Earnings Call Analysis
- Market cap
- ₹816 Cr
- P/E
- 102.69
- ROE
- 30.47%
- PEG
- 0.54
- Price to sales
- 10.07
- Debt to equity
- 0.43
- 52W high / low
- ₹502 / ₹132
- EBITDA margin
- 15.26%
- Net profit margin
- 9.92%
- Promoter holding
- 72.89%
- Sales (last year)
- ₹81 Cr
Incorporated in 2010, Aptus Pharma Ltd is engaged in the business of marketing and distribution of finished pharmaceutical formulations.[1]
Guidance scorecard · Q2 FY27 call
What Aptus Pharma's management guided
and where it ranks in Pharmaceuticals & Biotechnology
Pharmaceuticals & Biotechnology
RevenueQ2 FY27 call
20–40%- Aptus Pharma aims for rapid growth transitioning from a local to a national pharmaceutical player by 2029.
- Targeting 46% geographic coverage across India by March 2027, with plans to reach pan-India presence by 2029.
- Focus on expanding core prescription business, acute and chronic therapy portfolios, OTC and wellness segments.
- Manufacturing expansion planned by March 2028 to produce approximately 20% of product portfolio in-house, enhancing supply control.
- International expansion is a strategic goal with selective markets in Asia, Africa, and Latin America being evaluated.
- Expected growth is supported by an increasing distributor network (250+ distributors), product portfolio of 300+ formulations, and retail presence in 45,000+ outlets.
2 more points from Aptus Pharma's call on revenue
Create a free account to keep reading this call
MarginsQ2 FY27 call
See what Aptus Pharma said on margins — free account, 30 seconds.
CapexQ2 FY27 call
Planned- Aptus Pharma plans a manufacturing expansion with an initial CAPEX of approximately ₹35 crore.
- Out of this, around ₹25 crore will be funded through a preferential issue.
- The manufacturing facility will focus on producing about 20% of their product portfolio for self-consumption, with the remaining capacity aimed at exports to Rest of the World (ROW) countries.
- The CAPEX project is expected to be commissioned progressively, with the initial phase planned around March 2028.
- The company aims to strengthen its manufacturing capabilities to support supply chain efficiency, product availability, and brand portfolio control.
2 more points from Aptus Pharma's call on capex
Create a free account to keep reading this call
FundraisingQ2 FY27 call
PlannedSee what Aptus Pharma said on fundraising — free account, 30 seconds.
Order bookQ2 FY27 call
Ask what Aptus Pharma said on the order book →
Full Q2 FY27 analysisRanges are what management guided for revenue growth and margins on the latest earnings call. Not investment advice, and not a forecast of returns.
Potential multibaggers · Q2 FY27
Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Peers
Pharmaceuticals & Biotechnology companies ranked on guidance
| # | Company | Revenue guided | Margin guided | Market cap | P/E |
|---|---|---|---|---|---|
| 1 | 40%+ | Up 2%+ | ₹480 Cr | 19.1 | |
| 2 | 40%+ | Up 0–2% | ₹212 Cr | 16.1 | |
| 3 | 40%+ | Flat | ₹17,925 Cr | — | |
| 4 | 40%+ | Flat | ₹5,223 Cr | 39.1 | |
| 5 | 40%+ | Flat | ₹4,268 Cr | — | |
| 6 | 40%+ | Flat | ₹40 Cr | — |
Sign up free to see every company in the sector ranking and track Aptus Pharma.
Pro shows every company guiding 40%+ revenue growth →Full Pharmaceuticals & Biotechnology rankingAptus Pharma announcements
All announcements →- Fundraise / allotmentNotableAptus Pharma receives BSE in-principle approval for preferential equity issue
Financials of Aptus Pharma
Quarterly Results, Profit & Loss, Balance Sheet, Cash Flows, and Ratios are shown below as separate sections.
Financials of Aptus Pharma
Quarterly Results
Quarter-by-quarter operating performance
Financials of Aptus Pharma
Profit & Loss
Annual income statement trend
| Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|
| Sales + | 13.90 | 17.81 | 24.56 | 46.57 |
| Expenses + | 13.28 | 16.27 | 19.71 | 39.12 |
| Operating Profit | 0.62 | 1.54 | 4.85 | 7.45 |
| OPM % | 4.46% | 8.65% | 19.75% | 16.00% |
| Other Income + | 0.00 | 0.03 | 0.08 | 0.13 |
| Interest | 0.14 | 0.24 | 0.47 | 0.80 |
| Depreciation | 0.18 | 0.21 | 0.27 | 0.41 |
| Profit before tax | 0.30 | 1.12 | 4.19 | 6.37 |
| Tax % | 33.33% | 28.57% | 26.01% | 27.47% |
| Net Profit + | 0.19 | 0.80 | 3.10 | 4.62 |
| EPS in Rs | 2.38 | 10.00 | 2.48 | 2.69 |
| Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% |
Financials of Aptus Pharma
Balance Sheet
Capital structure and asset base
| Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|
| Equity Capital | 0.30 | 0.30 | 5.00 | 6.86 |
| Reserves | 0.67 | 1.47 | 1.97 | 16.49 |
| Borrowings + | 2.22 | 5.31 | 10.35 | 7.18 |
| Other Liabilities + | 3.02 | 2.95 | 4.60 | 13.00 |
| Total Liabilities | 6.21 | 10.03 | 21.92 | 43.53 |
| Fixed Assets + | 0.52 | 0.63 | 0.99 | 2.77 |
| CWIP | 0.00 | 0.00 | 0.00 | 0.00 |
| Investments | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Assets + | 5.69 | 9.40 | 20.93 | 40.76 |
| Total Assets | 6.21 | 10.03 | 21.92 | 43.53 |
Financials of Aptus Pharma
Cash Flows
Operating, investing and financing cash movement
| Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|
| Cash from Operating Activity + | -0.18 | -2.17 | -1.84 | -6.86 |
| Cash from Investing Activity + | -0.35 | -0.30 | -0.54 | -6.37 |
| Cash from Financing Activity + | 0.81 | 2.86 | 6.68 | 9.04 |
| Net Cash Flow | 0.28 | 0.38 | 4.30 | -4.19 |
| Free Cash Flow | -0.53 | -2.50 | -2.46 | -9.05 |
| CFO/OP | -10% | -119% | -15% | -76% |
Financials of Aptus Pharma
Ratios
Working capital efficiency and return ratios
| Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|
| Debtor Days | 63.02 | 68.66 | 83.82 | 147.03 |
| Inventory Days | 176.00 | 183.57 | 285.06 | 231.78 |
| Days Payable | 104.07 | 72.25 | 52.89 | 139.20 |
| Cash Conversion Cycle | 134.95 | 179.97 | 315.98 | 239.61 |
| Working Capital Days | 51.99 | 67.02 | 36.41 | 116.78 |
| ROCE % | 26.48% | 38.20% | 29.97% |
Momentum score · price trend
100 out of 100 — Strengthening
Over the past year its share price has done better than most of the stocks we track.
| Period | Share price change | Better than … of 1,910 stocks |
|---|---|---|
| Last 12 months | +971.0% | 100% |
| Last 6 months | +211.8% | 100% |
| Last 3 months | +96.4% | 100% |
How we calculate it
“Better than 30%” means that over that period the share price did better than 30 out of every 100 stocks we track (1,910 Indian companies worth ₹500 Cr or more, with at least a year of prices).
The score weighs the longer periods more: 40% × 12-month + 40% × 6-month + 20% × 3-month. For Aptus Pharma: 0.4 × 100 + 0.4 × 100 + 0.2 × 100 = 100.
Strengthening is 70 and above, Steady 40 to 70, Cooling below 40. Scores are recalculated every night after the market closes.
Full methodology →This describes only how the share price has moved up to 16 Oct 2026, compared with other stocks. It says nothing about the business, and it is not a prediction, a price target or a recommendation to buy or sell.
Continue your research
What Aptus Pharma's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- Anthem Bioscienc (Q2 FY27)
Q2FY27 Consolidated Revenue from Operations: ₹5,940 Mn, up 7.9% YoY from ₹5,505 Mn in Q2FY26 (Page 4). Key investor presentation takeaways from Anthem Bioscienc
- Neuland Laboratories (Q2 FY27)
Q2FY27 Total Income (revenue) was ₹457.2 crore, down 11.4% year-on-year (YoY) from Q2FY26. Key investor presentation takeaways from Neuland Laboratories Ltd's Q
- Hikal (Q2 FY27)
Consolidated Revenue Q2FY27:** ₹434 crores, up 36% YoY from ₹319 crores in Q2FY26 (Page 9) . Key investor presentation takeaways from Hikal Ltd's Q2 FY27 invest
- Kopran (Q2 FY27)
9,335 lakhs (~79% increase) . Key investor presentation takeaways from Kopran Ltd's Q2 FY27 investor presentation — and how it ranks against sector peers.